For research use only. Not Intended for Therapeutic Use!
|We would like to match the lowest price on market if possible.|
Defactinib Hcl (VS-6063; PF-04554878) is a potent FAK phosphorylation inhibitor; overcomes YB-1–mediated paclitaxel
resistance by an AKT-dependent pathway.
Target: FAK inhibitor
VS-6063 inhibited FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner. The combination of VS-6063 and paclitaxel markedly decreased proliferation and increased apoptosis, which resulted in 92.7% to 97.9% reductions in tumor weight. RPPA data showed that VS-6063 reduced levels of AKT and YB-1 in taxane-resistant cell lines. FAK inhibition enhanced chemosensitivity in taxane-resistant cells by decreasing YB-1 phosphorylation and subsequently CD44 in an AKT-dependent manner.
. Kang Y, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.